Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.
Non Small Cell Lung Cancer
DRUG: Immune checkpoint inhibitor
Progression-free survival (PFS), To assess progression-free survival of patients treated by different treatment according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator, define as first dose to first documented disease progression assessed by investigator or death due to any cause, Time from first subject dose to study completion, or up to 36 month
Overall survival (OS), To assess overall survival, define as first dose to the death of the subject due to any cause, Time from first subject dose to study completion, or up to 36 months.|Objective Response Rate (ORR), To assess ICI and TKIs overall response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Time from first subject dose to study completion, or up to 36 months.|Duration of Response (DOR), To assess duration of response for subjects with CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator , defined as the time from the first documented CR or PR to disease progression or death, Time from first subject dose to study completion, or up to 36 month|Adverse events (AEs) according to CTCAE 5.0, Number of participants with adverse events (AEs) according to CTCAE 5.0, From first dose until 28 days after the last dose, up to 24 month|Patient reported outcome, Patient reported outcomes (PROs): A report that directly reflects a patient's assessment of their own health status., Time from first subject dose to study completion, or up to 36 months.
This prospective study aimed to assess its efficacy and adverse event for Checkpoint Inhibitors with or without chemotherapy in clincial practice. Several cohorts were devided including pathological type, treatment line, treatment regiems, combination strategies. Tissue samples were collected with permission of patients for TME evaluation.